Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 1, 2017
LEXINGTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Sep 22, 2017
LEXINGTON, Mass., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
-
Sep 14, 2017
LEXINGTON, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its...
-
Sep 11, 2017Results from 34 Patients Demonstrate Positive Safety Profile and Support Decision to Expand Development
LEXINGTON, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
-
Sep 6, 2017
LEXINGTON, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics...
-
Aug 31, 2017
LEXINGTON, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
-
Aug 16, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 16, 2007--Curis, Inc. (NASDAQ:CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today...
-
Aug 3, 2017Management to host conference call today at 8:30 a.m. EDT
LEXINGTON, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Jul 26, 2017
LEXINGTON, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Jul 5, 2017
LEXINGTON, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Jun 1, 2017
LEXINGTON, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
-
May 25, 2017
LEXINGTON, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...
-
May 4, 2017Management to host conference call today at 8:30 a.m. EDT
LEXINGTON, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Apr 28, 2017
LEXINGTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Apr 5, 2017
LEXINGTON, Mass., April 05, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Mar 30, 2017
LEXINGTON, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Mar 16, 2017
LEXINGTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- March 16, 2017 - Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug...
-
Mar 9, 2017Company Announces $45 million Debt Transaction with HealthCare Royalty Partners Secured with Future Erivedge® Royalty
LEXINGTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Mar 7, 2017
LEXINGTON, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Mar 1, 2017
LEXINGTON, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Feb 17, 2017
LEXINGTON, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Feb 7, 2017Curis to Release Second Quarter 2007 Financial Results and Hold Conference Call on February 14, 2008
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today...
-
Jan 9, 2017Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration
LEXINGTON, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Jan 6, 2017
LEXINGTON, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Nov 28, 2016
LEXINGTON, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...